Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin
Vashisht R, Jung K, Schuler A, Banda J, Park R, Jin S, Li L, Dudley J, Johnson K, Shervey M, Xu H, Wu Y, Natrajan K, Hripcsak G, Jin P, Van Zandt M, Reckard A, Reich C, Weaver J, Schuemie M, Ryan P, Callahan A, Shah N. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin. JAMA Network Open 2018, 1: e181755. PMID: 30646124, PMCID: PMC6324274, DOI: 10.1001/jamanetworkopen.2018.1755.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMetforminSulfonylurea CompoundsThiazolidinedionesConceptsDPP-4 inhibitorsDipeptidyl peptidase-4 inhibitorsFirst-line therapyPeptidase-4 inhibitorsSecond-line drugsType 2 diabetesMyocardial infarctionEye disordersKidney disordersDrug classesSecond-line treatment choiceTotal hemoglobinObservational Health Data SciencesSecond-line treatment optionNew-user cohort studyEffectiveness of sulfonylureasSecond-line treatmentHemoglobin A1c levelsUse of sulfonylureasHealth Data SciencesLarge international studyElectronic medical recordsRoutine medical practiceInsurance claims dataCohort study